127 related articles for article (PubMed ID: 38442535)
1. Experience of patients on methadone maintenance treatment receiving take-home methadone doses during COVID-19 pandemic: A multi-site study from India.
Kathiresan P; Patel V; Jangra J; Chattopadhyay A; Abdus S; Jadhav M; Rao R; Arya A; Bansal PD; Chinggouman C; Bhad R; Ambekar A; Agrawal A; Chatterjee B; Yadav D
Asian J Psychiatr; 2024 May; 95():103979. PubMed ID: 38442535
[TBL] [Abstract][Full Text] [Related]
2. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
3. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic.
Dunn KE; Brooner RK; Stoller KB
J Subst Abuse Treat; 2021 Feb; 121():108197. PubMed ID: 33357606
[TBL] [Abstract][Full Text] [Related]
4. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19.
Figgatt MC; Salazar Z; Day E; Vincent L; Dasgupta N
J Subst Abuse Treat; 2021 Apr; 123():108276. PubMed ID: 33612201
[TBL] [Abstract][Full Text] [Related]
5. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
[TBL] [Abstract][Full Text] [Related]
6. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
[No Abstract] [Full Text] [Related]
7. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
Saulle R; Vecchi S; Gowing L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
[TBL] [Abstract][Full Text] [Related]
8. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.
Levander XA; Hoffman KA; McIlveen JW; McCarty D; Terashima JP; Korthuis PT
Addict Sci Clin Pract; 2021 Dec; 16(1):72. PubMed ID: 34895346
[TBL] [Abstract][Full Text] [Related]
9. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
Brothers S; Viera A; Heimer R
J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
[TBL] [Abstract][Full Text] [Related]
10. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D
J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443
[TBL] [Abstract][Full Text] [Related]
11. Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care?
Trujols J; Larrabeiti A; Sànchez O; Madrid M; De Andrés S; Duran-Sindreu S
J Subst Abuse Treat; 2020 Dec; 119():108154. PubMed ID: 33032860
[TBL] [Abstract][Full Text] [Related]
12. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
[No Abstract] [Full Text] [Related]
13. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic.
Hallgren KA; Darnton J; Soth S; Blalock KL; Michaels A; Grekin P; Saxon AJ; Woolworth S; Tsui JI
J Subst Abuse Treat; 2022 Dec; 143():108896. PubMed ID: 36215911
[TBL] [Abstract][Full Text] [Related]
14. Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids.
Panwala V; Thorn E; Amiri S; Socias ME; Lutz R; Amram O
Am J Drug Alcohol Abuse; 2023 Sep; 49(5):597-605. PubMed ID: 37433122
[No Abstract] [Full Text] [Related]
15. "It didn't hurt me": patients' and providers' perspectives on unsupervised take-home doses, drug diversion, and overdose risks in the provision of medication for opioid use disorder during COVID-19 in San Juan, Puerto Rico.
Abadie R; Fisher CB
Harm Reduct J; 2024 Apr; 21(1):85. PubMed ID: 38664796
[TBL] [Abstract][Full Text] [Related]
16. COVID-19-related flexibility in methadone take-home doses associated with decreased attrition: Report from an opioid treatment program in central Pennsylvania.
Kawasaki SS; Zimmerman R; Shen C; Zgierska AE
J Subst Use Addict Treat; 2023 Dec; 155():209164. PubMed ID: 37730014
[TBL] [Abstract][Full Text] [Related]
17. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
[TBL] [Abstract][Full Text] [Related]
18. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.
Wu LT; John WS; Morse ED; Adkins S; Pippin J; Brooner RK; Schwartz RP
Addiction; 2022 Feb; 117(2):444-456. PubMed ID: 34286886
[TBL] [Abstract][Full Text] [Related]
19. Changes in methadone take-home dosing before and after COVID-19.
Amram O; Amiri S; Thorn EL; Lutz R; Joudrey PJ
J Subst Abuse Treat; 2022 Feb; 133():108552. PubMed ID: 34304950
[TBL] [Abstract][Full Text] [Related]
20. Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance.
Gerra G; Saenz E; Busse A; Maremmani I; Ciccocioppo R; Zaimovic A; Gerra ML; Amore M; Manfredini M; Donnini C; Somaini L
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):483-9. PubMed ID: 21147192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
